Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
ABSTRACT Background Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point, be offered to placebo participants, which will occur before long-term efficacy and safety are known.Methods Following vaccination of the placebo group, we show that placebo-controlled vaccine efficacy can be derived by assuming the benefit of vaccination over time has the same profile for the original vaccine recipients and the placebo crossovers. This reconstruction allows estimation of both vaccine durability and potential vaccine-associated enhanced disease.Results Post-crossover estimates of vaccine efficacy can provide insights about durability, identify waning efficacy, and identify late enhancement of disease, but are less reliable estimates than those obtained by a standard trial where the placebo cohort is maintained. As vaccine efficacy estimates for post-crossover periods depend on prior vaccine efficacy estimates, longer pre-crossover periods with higher case counts provide better estimates of late vaccine efficacy. Further, open-label crossover may lead to riskier behavior in the immediate crossover period for the unblinded vaccine arm, confounding vaccine efficacy estimates for all post-crossover periods.Conclusions We advocate blinded crossover and continued follow-up of trial participants to best assess vaccine durability and potential delayed enhancement of disease. This approach allows placebo recipients timely access to the vaccine when it would no longer be proper to maintain participants on placebo, yet still allows important insights about immunological and clinical effectiveness over time..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 06. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Follmann, Dean [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.12.14.20248137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019562918 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019562918 | ||
| 003 | DE-627 | ||
| 005 | 20230429095936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201218s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.14.20248137 |2 doi | |
| 035 | |a (DE-627)XBI019562918 | ||
| 035 | |a (biorXiv)10.1101/2020.12.14.20248137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Follmann, Dean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point, be offered to placebo participants, which will occur before long-term efficacy and safety are known.Methods Following vaccination of the placebo group, we show that placebo-controlled vaccine efficacy can be derived by assuming the benefit of vaccination over time has the same profile for the original vaccine recipients and the placebo crossovers. This reconstruction allows estimation of both vaccine durability and potential vaccine-associated enhanced disease.Results Post-crossover estimates of vaccine efficacy can provide insights about durability, identify waning efficacy, and identify late enhancement of disease, but are less reliable estimates than those obtained by a standard trial where the placebo cohort is maintained. As vaccine efficacy estimates for post-crossover periods depend on prior vaccine efficacy estimates, longer pre-crossover periods with higher case counts provide better estimates of late vaccine efficacy. Further, open-label crossover may lead to riskier behavior in the immediate crossover period for the unblinded vaccine arm, confounding vaccine efficacy estimates for all post-crossover periods.Conclusions We advocate blinded crossover and continued follow-up of trial participants to best assess vaccine durability and potential delayed enhancement of disease. This approach allows placebo recipients timely access to the vaccine when it would no longer be proper to maintain participants on placebo, yet still allows important insights about immunological and clinical effectiveness over time. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Fintzi, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Fay, Michael P. |e verfasserin |4 aut | |
| 700 | 1 | |a Janes, Holly E. |e verfasserin |4 aut | |
| 700 | 1 | |a Baden, Lindsey |e verfasserin |4 aut | |
| 700 | 1 | |a Sahly, Hana El |e verfasserin |4 aut | |
| 700 | 1 | |a Fleming, Thomas R. |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrotra, Devan V. |e verfasserin |4 aut | |
| 700 | 1 | |a Carpp, Lindsay N. |e verfasserin |4 aut | |
| 700 | 1 | |a Juraska, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Benkeser, David |e verfasserin |4 aut | |
| 700 | 1 | |a Donnell, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Fong, Youyi |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yunda |e verfasserin |4 aut | |
| 700 | 1 | |a Hyrien, Ollivier |e verfasserin |4 aut | |
| 700 | 1 | |a Luedtke, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Carone, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Nason, Martha |e verfasserin |4 aut | |
| 700 | 1 | |a Vandebosch, An |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Honghong |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Iksung |e verfasserin |4 aut | |
| 700 | 1 | |a Gabriel, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Kublin, James G. |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Myron S. |e verfasserin |4 aut | |
| 700 | 1 | |a Corey, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Peter B. |e verfasserin |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 06. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:06 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.7326/M20-8149 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.14.20248137 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 06 |c 12 | ||